AI brief of an SEC Form 8-K · STAAR Surgical (STAA)

STAAR Surgical names former CEO David Bailey as Chief Commercial Officer

Neutral Impact 3 of 5 leadership Written later

STAAR Surgical appointed David Bailey, its former President and Chief Executive Officer, as Chief Commercial Officer effective September 8, 2026. He reports to CEO Warren Foust, and the filing sets out his base salary, bonus target and equity awards, which shareholders can review in the offer letter filed as Exhibit 10.1.

Key points

Appointed Chief Commercial Officer effective September 8, 2026; reports to Warren Foust, President and CEO
Base salary at an annual rate of CHF 462,825 (approximately $575,000), with a 2026 target bonus of 60% of base salary, prorated
Initial RSU grant valued at $850,000 vesting over three years, plus a 2026 long-term incentive award valued at $1,400,000, prorated
Mr. Bailey previously served as STAAR's President and CEO from 2001 to 2008 and as President, International Operations, from 2008 to 2011

The filing

CompanySTAAR Surgical (STAA)

Form8-K, current report

Filed with the SECSep 9, 2026, 5:37 PM ET

Accession number0001193125-26-386662

Items reported: 5.02 Director / Officer Change 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 6:57 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 09, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.